Karuna Therapeutics Inc. (KRTX)
329.83
0.09 (0.03%)
At close: Mar 15, 2024, 8:00 PM
0.03% (1D)
| Bid | n/a |
| Market Cap | 12.6B |
| Revenue (ttm) | 654K |
| Net Income (ttm) | -422.19M |
| EPS (ttm) | -11.74 |
| PE Ratio (ttm) | -28.094548551959114 |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | n/a |
| Volume | 1,283,005 |
| Avg. Volume (20D) | 971,825 |
| Open | 329.75 |
| Previous Close | 329.74 |
| Day's Range | 329.75 - 329.97 |
| 52-Week Range | 158.38 - 329.99 |
| Beta | 1.15 |
About KRTX
Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate is KarXT, an oral modulator of muscarinic receptors that is in Phase III clinical trial for the treatment of acute psychosis in patients with schizophrenia; and for the treatment of central nervous system disorders, such as negative and cogni...
Industry Biotechnology
Sector Healthcare
IPO Date Jun 28, 2019
Employees 339
Stock Exchange NASDAQ
Ticker Symbol KRTX
Website https://www.karunatx.com